BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25019570)

  • 1. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study.
    Hsu KF; Chou HH; Huang CY; Fu HC; Chiang AJ; Tsai HW; Chen JR; Cheng WF; Ke YM; Chang CC; Chen TH; Lin SH; Ho CM
    Gynecol Oncol; 2014 Sep; 134(3):516-22. PubMed ID: 25019570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
    Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
    Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review.
    Thomas M; Mariani A; Wright JD; Madarek EO; Powell MA; Mutch DG; Podratz KC; Dowdy SC
    Gynecol Oncol; 2008 Feb; 108(2):293-7. PubMed ID: 18096208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study.
    Sarı ME; Meydanlı MM; Türkmen O; Cömert GK; Turan AT; Karalök A; Şahin H; Haberal A; Kocaman E; Akbayır Ö; Erdem B; Numanoğlu C; Güngördük K; Sancı M; Gökçü M; Özgül N; Salman MC; Boyraz G; Yüce K; Güngör T; Taşkın S; Altın D; Ortaç UF; Ayık HA; Şimşek T; Arvas M; Ayhan A
    J Gynecol Oncol; 2017 Jul; 28(4):e49. PubMed ID: 28541637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
    Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
    Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy of uterine clear cell carcinoma: a review.
    Xu Y; Hanna RK; Elshaikh MA
    Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine Clear Cell Carcinoma: Does Adjuvant Chemotherapy Improve Outcomes?
    Nguyen JM; Bouchard-Fortier G; Bernardini MQ; Atenafu EG; Han G; Vicus D; Ferguson SE; Gien LT
    Int J Gynecol Cancer; 2017 Jan; 27(1):69-76. PubMed ID: 27668398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
    Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
    J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
    Armbruster SD; Previs R; Soliman PT; Westin SN; Fellman B; Jhingran A; Fleming ND
    Gynecol Oncol; 2019 Aug; 154(2):328-332. PubMed ID: 31221496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
    Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
    Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
    Ayeni TA; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; Haddock MG; Keeney GL; Long HJ; Dowdy SC; Podratz KC
    Gynecol Oncol; 2013 Jun; 129(3):478-85. PubMed ID: 23535279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
    Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
    Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
    Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
    Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis.
    Gockley AA; Rauh-Hain JA; Anders AM; Meyer LA; Clemmer J; Lu KH; Clark RM; Schorge JO; del Carmen MG
    Int J Gynecol Cancer; 2016 May; 26(4):697-704. PubMed ID: 26825834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of lymphadenectomy in uterine clear cell carcinoma.
    Mahdi H; Lockhart D; Moselmi-Kebria M
    J Gynecol Oncol; 2015 Apr; 26(2):134-40. PubMed ID: 25686398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hysterectomy for uterine adenocarcinoma in the elderly: tumor characteristics, and long-term outcome.
    Gayar OH; Robbins JR; Parikh K; Lu M; Buekers T; Munkarah A; Elshaikh MA
    Gynecol Oncol; 2011 Oct; 123(1):71-5. PubMed ID: 21767871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
    Bristow RE; Asrari F; Trimble EL; Montz FJ
    Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.